Fourth-generation cryoablation based left atrial appendage isolation for the treatment of persistent atrial fibrillation: First case report

Roland Richard Tilz*, Makoto Sano, Julia Vogler, Thomas Fink, Charlotte Eitel, Christian H. Heeger

*Corresponding author for this work
5 Citations (Scopus)

Abstract

Objective: Background: Case Report: Conclusions: Unusual or unexpected effect of treatment Pulmonary vein isolation (PVI) is an effective treatment strategy for patients with paroxysmal atrial fibrillation (AF), yet it is associated with limited success rates in patients with persistent AF (PersAF). The left atrial appendage (LAA) was recently identified as a target of catheter ablation especially in PVI non-responders and LAA-isolation (LAAI) by cryoballoon or radiofrequency was shown to be effective. Recently the fourth-generation cryoballoon (CB4) was introduced to clinical practice. Here we are demonstrating the first case report of CB4-based LAAI followed by LAA-closure in a patient with PersAF. A 67-year-old male patient presented with symptomatic PersAF and thromboembolism due to LAA-thrombus. After resolving the LAA-thrombus cryoballoon based PVI and empirical LAAI was successfully performed. To prevent further thromboembolism LAA-closure was successfully performed after 6 weeks. On short-term follow-up (12 weeks) the patients stayed in stable sinus rhythm. Fourth-generation cryoballoon based ablation seems to be an effective treatment strategy for LAAI.

Original languageEnglish
JournalAmerican Journal of Case Reports
Volume20
Pages (from-to)1830-1836
Number of pages7
DOIs
Publication statusPublished - 2019

Funding

Roland Richard Tilz, e-mail: [email protected] Christian-H. Heeger received travel grants and research grants by Medtronic, Claret Medical, SentreHeart, Biosense Webster and Cardiofocus. Roland Richard Tilz received travel grants from St. Jude Medical, Topera, Biosense Webster, Daiichi Sankyo, SentreHeart and Speaker’s Bureau Honoraria from Biosense Webster, Biotronik, Pfizer, Topera, Bristol-Myers Squibb; Bayer, Sano Aventis and research grants by Cardiofocus. Charlotte Eitel received travel grants and educational grants from Biosense Webster, Medtronic, Biotronik, Abbott and Daiichi Sankyo, speaker‘s honoraria from Biosense Webster, Medtronic, Abbott, Sentrheart and Daiichi Sankyo. All other authors have no relevant disclosures

Fingerprint

Dive into the research topics of 'Fourth-generation cryoablation based left atrial appendage isolation for the treatment of persistent atrial fibrillation: First case report'. Together they form a unique fingerprint.

Cite this